» Articles » PMID: 25939989

[The Wearable Cardioverter-Defibrillator (WCD)]

Overview
Date 2015 May 6
PMID 25939989
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

While the implantable cardioverter-defibrillator (ICD) has been proven to be the best choice for patients with long-term risk for sudden cardiac arrest/sudden cardiac death (SCA/SCD), the question is how to manage patients with only temporary risk, e.g., during the guidelines-recommended waiting period until the decision for an ICD can be made. These patient groups should be monitored around the clock to guarantee a lifesaving shock within a few minutes, if necessary.These conditions can be accomplished by the wearable cardioverter-defibrillator (WCD) in the outpatient sector. The WCD is worn on the skin and consists of four nonadhesive ECG electrodes as well as three defibrillation electrodes-two at the back and one at the front-embedded in a garment. The defibrillation unit is connected via a cord and can be worn over the shoulder or on a belt. Cardiac events can be recorded and retrospectively analyzed by the treating physician.The WCD is a safe and effective measure to terminate potentially lethal ventricular tachycardia and ventricular fibrillation. It may be used early after myocardial infarction with reduced left ventricular ejection fraction (LVEF), as well as for patients with acute heart failure in nonischemic cardiomyopathy with uncertain cause and prognosis. In addition, it may be used for patients waiting for heart transplantation, for patients who cannot be implanted an ICD due to comorbidities, and for patients after explantation of their ICD, e.g., because of infection until reimplantation.One may expect that risk stratification of patients with the WCD will lead to even better selection for ICD use.

Citing Articles

Wearable Cardioverter-Defibrillator Used as a Telemonitoring System in a Real-Life Heart Failure Unit Setting.

Blockhaus C, List S, Waibler H, Gulker J, Klues H, Bufe A J Clin Med. 2021; 10(22).

PMID: 34830724 PMC: 8618886. DOI: 10.3390/jcm10225435.


[Present and future relevance of telemedicine in cardiac arrhythmia emergencies].

Schwab J, Helms T Herzschrittmacherther Elektrophysiol. 2020; 31(1):73-76.

PMID: 32020271 DOI: 10.1007/s00399-020-00671-1.

References
1.
Solomon S, Glynn R, Greaves S, Ajani U, Rouleau J, Menapace F . Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med. 2001; 134(6):451-8. DOI: 10.7326/0003-4819-134-6-200103200-00009. View

2.
Epstein A, Abraham W, Bianco N, Kern K, Mirro M, Rao S . Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol. 2013; 62(21):2000-2007. DOI: 10.1016/j.jacc.2013.05.086. View

3.
Zishiri E, Williams S, Cronin E, Blackstone E, Ellis S, Roselli E . Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2013; 6(1):117-28. PMC: 3676862. DOI: 10.1161/CIRCEP.112.973552. View

4.
Wilkoff B, Love C, Byrd C, Bongiorni M, Carrillo R, Crossley 3rd G . Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm. 2009; 6(7):1085-104. DOI: 10.1016/j.hrthm.2009.05.020. View

5.
Halkin A, Singh M, Nikolsky E, Grines C, Tcheng J, Garcia E . Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005; 45(9):1397-405. DOI: 10.1016/j.jacc.2005.01.041. View